FDA approves Azurity Pharmaceuticals’ Danziten for CML treatment
The approval is expected to enhance patient adherence to treatment via eliminating the need for fasting.
Approvals
Health Canada approves GSK’s Ojjaara for myelofibrosis in anaemia patients
Zai Lab and argenx announce NMPA approval for sBLA for VYVGART Hytrulo
FDA grants breakthrough status to J&J’s nipocalimab for SjD treatment
Ipsen’s Elafibranor gains MHRA approval for PBC treatment
J&J clinches EC approval for first single-pill PAH combo
BMS wins approval for schizophrenia drug acquired from Karuna
MHLW approves MSD’s KEYTRUDA for lung and urothelial cancers
